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[Arg8]-vasopressin (AVP) has several functions via its three
distinct receptors, V1a, V1b, and V2. The V1a vasopressin
receptor (V1aR) is expressed in blood vessels and involved
in vascular contraction. Recently, we generated V1a
receptor–deficient (V1aR/) mice and found that they were
hypotensive. In addition, V1aR/ mice exhibited (1) blunted
AVP-induced vasopressor response, (2) impaired arterial
baroreceptor reflex, (3) decreased sympathetic nerve activity,
and (4) decreased blood volume, all of which could
contribute to the observed hypotension. In relation to their
decreased blood volume, V1aR/ mice had decreased
plasma aldosterone levels, which could result not only from
decreased activity of the renin–angiotensin system (RAS), but
also from impaired AVP-stimulated aldosterone release in the
adrenal glands. V1aR was found to specifically co-express at
the macula densa cells with cyclooxygenase (COX)-2 and with
neuronal nitric oxide synthase, which produces potent
stimulators of renin, PGE2, and NO. The expression levels of
renin, COX-2, and nNOS were significantly decreased in
V1aR/ mice, which led to the suppression of RAS activity
and consequent decreases in aldosterone and blood volume.
Furthermore, V1aR is also expressed in collecting duct cells
and involved in regulating water reabsorption by affecting
V2/aquaporin 2 function. Thus, AVP regulates blood pressure
and volume via V1aR by exerting diverse functions in vivo.
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AVP RECEPTORS AND KNOCKOUT MICE
The neurohypophyseal peptide [Arg8]-vasopressin (AVP) is
involved in diverse functions including regulation of body
fluid homeostasis, vasoconstriction, and adrenocorticotropic
hormone release. These physiological effects are mediated by
three subtypes of AVP receptors, designated V1a, V1b, and
V2.1 The V1a vasopressin receptor (V1aR) is widely
expressed, whereas the V1b receptor (V1bR) is specifically
expressed in the anterior pituitary glands and pancreatic
islets; the V2 receptor (V2R) is predominantly expressed in
the kidneys.1,2 V1aR mediates vascular contraction, cellular
proliferation, platelet aggregation, glycogenolysis, lipid me-
tabolism, protein catabolism, and glucose tolerance.1,2 V1bR
mediates adrenocorticotropic hormone and insulin release.2
Both V1aR and V1bR couple to the Gq protein and act
through phosphatidylinositol hydrolysis to mobilize inter-
cellular Ca2þ .1 V2R is expressed in the thick ascending limbs
(TAL) of Henle’s loop and the collecting ducts in the kidney.
Through V2R, AVP stimulates Gs protein and adenylate
cyclase to increase cellular cAMP, which stimulates the
translocation of aquaporin (AQP)-2 in the collecting duct,
and thereby increases water resorption.1 As V1aR and V2R
are both detected in the juxtaglomerular apparatus, the TAL,
and the collecting duct, both could be involved in regulating
body fluid homeostasis.1,3
Recently, we generated mice deficient in either V1a
(V1aR/) or V1b (V1bR/). As AVP exerts its various
actions through V1aR and V1bR, as well as through V2R,
mutant mice deficient in V1aR or V1bR exhibit a variety of
phenotypes. Although V1bR/ mice exhibited altered
hypothalamic–pituitary–adrenal axis activity,2 enhanced
insulin sensitivity,2 and altered psychological behavior,4
V1aR/mice also exhibited alterations in endocrine activity,
metabolism, and feeding and social behavior.2,5,6 In addition,
V1aR/ mice showed hypotension accompanied with
decreased plasma volume.5,7
In this review, we suggest possible mechanism(s) by which
AVP/V1aR may regulate blood pressure based on our studies
with V1aR/ mice.
BLOOD PRESSURE IN V1aR/ MICE
Blood pressure is regulated by many vasoactive factors such
as epinephrine.8 Among them, AVP is one of the most potent
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vasoconstrictors and is known to affect blood pressure by
regulating vascular tonus and body fluid through V1aR
and/or V2R.1 Yet the role of AVP in blood pressure
maintenance is ill-defined, as the cardiovascular effects of
AVP are complex. We studied the role of V1aR by observing
V1aR/ mice, and found that the mutant mice are
hypotensive.7 Although vascular V1aR is well recognized,
the hypotensive phenotype of V1aR/ mice was unexpected,
because previous pharmacological studies with selective
V1aR antagonists showed that blocking V1aR did not induce
any significant change in basal blood pressure level.9 There-
fore, participation of vascular V1aR in maintaining periph-
eral vascular tonus is unexpectedly small or nonexistent in
normal animals and humans at resting state. To elucidate the
possible mechanism(s) by which AVP/V1aR regulates blood
pressure, we analyzed V1aR/ mice and found several
changes that could affect blood pressure homeostasis.
Blunted AVP-induced vasopressor response
V1aR/ mice exhibited remarkable hypotension without a
significant change in heart rate during rest.7 An echocardio-
gram study revealed no difference in cardiac function
between V1aR/ and wild-type (WT) mice.7 As AVP is a
potent vasoconstrictor, pressor responses to AVP were
assessed in perfused mesenteric arterial beds. Whereas
isolated perfused mesenteric arterial beds from WT and
V1aR/ mice exhibited comparable responses to KCl, the
pressor response to AVP seen in WT mice was absent in
V1aR/ mice, indicating that the AVP-induced vascular
contraction was caused primarily through V1aR.7 In addition
to this in vitro finding, in vivo AVP-induced pressor response
was abolished in non-anesthetized V1aR/ mice, which
seemed at first to imply that a blunted blood pressure
response to AVP could cause the hypotension. However,
vasodilatation and depressor responses were induced in
V1aR/ arterial beds and non-anesthetized animals, respec-
tively, by high concentrations of AVP far exceeding the
physiological range.1,7,10 Considering our finding and other
reports on V1aR antagonists, it seems that other cause(s),
rather than the blunted AVP-induced pressor response, could
contribute to the decreased blood pressure observed in
V1aR/ mice.
Impaired arterial baroreceptor reflex
Functional relationships between blood pressure and reflex
changes in heart rate were examined in non-anesthetized
mice. We found that baroreceptor reflexes in V1aR/ mice
were significantly impaired. When blood pressure was
increased by phenylephrine, an a1 adrenergic receptor
agonist, or decreased by nitrates, markedly attenuated heart
rate changes were evident in V1aR/ mice and in WT mice
treated with a selective V1aR blocker, although blood
pressure changed by similar amounts in the mutants and
the control mice.7 Our observation was in line with the
attenuated baroreflex sensitivity seen in AVP-deficient rats,
and indicates involvement of V1aR in that reflex.11 In
addition, the bradycardia induced by electrical stimulation of
the hemilateral vagus nerve, which was exposed and cut at
the cervical level, was markedly attenuated in V1aR/ mice,
suggesting that their central baroreflex arc is impaired.12
When V1aR expression in the nucleus of the solitary tract
where the vagal afferents terminate was examined through in
situ hybridization analysis, V1aR was highly expressed in the
nucleus of the solitary tract and area postrema in WT mice,
but not in V1aR/. Thus, V1aR in the central nervous
system could have a crucial role in maintaining the baroreflex
control of heart rate and blood pressure homeostasis.
Decreased sympathetic nerve activity in central nervous
system
Although previous pharmacological studies with selective
V1aR antagonists did not induce any significant change in
basal blood pressure level, such drugs can exert a hypotensive
effect in hypertensive animals.9,13 This suggests that the
AVP/V1aR signal could be involved in developing or
maintaining hypertension. To clarify the underlying mechan-
isms, we generated a salt-induced hypertension model. In
WT mice, blood pressure was significantly increased during
salt loading after subtotal nephrectomy. In V1aR/ mice, in
contrast, blood pressure increased during salt loading, but
the final blood pressure after salt loading was significantly
lower, indicating that V1aR deficiency leads to resistance to
salt-induced hypertension (Koshimizu T et al., manuscript in
preparation). Plasma norepinephrine levels were increased by
the salt loading in both WT and V1aR/ mice, but the
increase in norepinephrine was smaller in V1aR/ mice,
suggesting that sympathetic nerve activity was suppressed in
V1aR/ mice. Furthermore, V1aR antagonists markedly
lowered the blood pressure in salt-loaded WT mice, but not
in control WT mice or in salt-loaded or control V1aR/
mice. Related to the salt-loaded hypertension model are
several previous studies involving crosses of genetically
hypertensive rat strains with vasopressin-deficient Brattle-
boro rats, intended to evaluate the importance of AVP in the
development of hypertension. These studies revealed that
genetic background contributes to salt- and water-retention
ability.14,15 SHRs (stroke-prone spontaneously hypertensive
rats) have normal extracellular fluid volumes and become
hypertensive on salt loading,16,17 whereas New Zealand
genetically hypertensive (NZGH) rats have reduced extra-
cellular fluid volumes and are insensitive to salt loading.18,19
When crossed with Brattleboro rats, vasopressin-deficient
SHR developed full hypertension,14 whereas the blood
pressures of vasopressin-deficient NZGH rats were lower
than those of the original NZGH strain.15 It seems that the
blood pressure phenotype of V1aR/ mice is more similar
to that of NZGH than to that of SHR, because AVP action is
indispensable for the basal blood pressure seen in V1aR/
mice, as it is for the hypertensive response seen in
NZGH rats.
We also examined the role of central V1aR in blood
pressure control by administering AVP into the cerebral
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ventricle and found that, whereas pressor and tachycardiac
responses were induced in WTmice in a sympathetic activity-
dependent manner, these events were completely abolished
in V1aR/ mice. In addition, pressor and tachycardiac
responses induced by hypertonic saline in the cerebral
ventricle were greatly diminished in V1aR/ mice compared
with those in WT mice. These findings imply that centrally
acting AVP has a crucial role in developing or maintaining
hypertension by stimulating sympathetic nerve activity
through V1aR.
Decreased plasma volume in V1aR/ mice
In investigating the mechanism(s) responsible for the
observed hypotension in V1aR/ mice, we found that their
circulating blood volume was significantly reduced by 9%.7
This reduction could be a major factor, if not the only factor,
contributing to the lowered resting blood pressure observed
in V1aR/ mice.
Lower plasma volume due to the decreased plasma aldosterone
level in V1aR/ mice. To investigate the mechanism under-
lying the reduction in blood volume, we further examined
hematocrit, blood urea nitrogen, plasma AVP, atrial natriuretic
peptide, and aldosterone in V1aR/ mice. V1aR/ mice had
higher hematocrit, blood urea nitrogen, and plasma AVP
values,5 and lower atrial natriuretic peptide, and aldosterone
levels, compared with WTmice.5 In addition, urine volume of
V1aR/ mice was higher than that of WT mice under both
basal and water-loading conditions.20 These findings suggest
that the decrease in aldosterone level could be a cause of the
impaired regulation of body fluid retention seen in V1aR/
mice, which led to their decreased circulating blood volume.
Before this hypothesis is accepted, however, it needs to be
proven experimentally by restoring aldosterone levels in
V1aR/ mice to normal, and measuring their blood pressure
and blood volume.5,7 In the study with the mineralocorticoid
receptor-deficient mice, mentioned above, the mutant mice
exhibited dehydration accompanied by higher hematocrit
levels than those seen in WTmice;21 this finding supports our
observation that V1aR/ mice also suffer from dehydration.
Decreased plasma aldosterone level due to the decreased
RAS activity in V1aR/ mice. As we found that the blood
pressure, plasma volume, and aldosterone level were
decreased in V1aR/ mice,5,7 we evaluated the activity of
the renin–angiotensin system (RAS).
We found that plasma renin activity and angiotensin II
levels were decreased in V1aR/ mice compared with those
in WT mice under both basal and water-restricted condi-
tions,20 implicating that RAS activity was suppressed in
V1aR/ mice. To further confirm the decreased renin
activity, we investigated renin expression in the kidney. Renin
in the granule cells was detected through immunohisto-
chemical study as previously described.22 In a control kidney,
renin expression was detected not only in the granule cells
but also in the renal tubules.20,23 In the V1aR/ kidney,
renin was expressed in the same two locations, but at
significantly lower levels, indicating that decreased expression
of renin underlies the decreased renin activity in V1aR/
mice.20 In good agreement with this finding, renin expres-
sions at the mRNA and protein levels were also decreased in
V1aR/ mice compared with those in WTmice under basal
and water-restricted conditions.20 As neuronal nitric oxide
synthase (nNOS), which is expressed in macula densa cells,
and cyclooxygenase (COX)-2, expressed in macula densa cells
and the TAL, also have important roles in tubuloglomerular
feedback by producing NO and prostaglandin E2, and
stimulating renin production in granule cells,22 we next
compared the expressions of nNOS and COX-2 between WT
and V1aR/ mice. In both WT and V1aR/ kidneys, an
immunohistochemical study revealed that nNOS was speci-
fically expressed in macula densa cells and COX-2 was
present in macula densa cells and TAL, but the expressions of
nNOS and COX-2 were weaker in V1aR/ kidney.20 In
agreement with the decreased COX-2 expression, urinary
and plasma prostaglandin E2 levels were also decreased in
V1aR/ mice.20 In addition to this local stimulation of renin
production, sympathetic nerve activity also has a crucial role in
renin secretion.24 These findings and those of other previous
reports suggest that a blunted ability to regulate renin produc-
tion in granule cells and the TAL due to impairment of both
local and central stimulation processes caused the decrease in
renin production in V1aR/ mice, which contributed to their
low plasma volume and hypotension.
AVP is well known to regulate body fluid homeostasis
through the V2R–AQP2 system in the kidney. In contrast, the
functional role of V1aR in the kidney has not been fully
elucidated even though it has been localized in several regions
of the kidney, including TAL, collecting ducts, and renal
vascular cells.3 As the expression levels of nNOS and COX-2
were decreased in V1aR/ mouse kidneys, we performed in
situ hybridization for V1aR in WT mouse kidney to
determine whether V1aR was coexpressed with nNOS or
COX-2. V1aR was detected in the macula densa cells, where it
was co-localized with nNOS and COX-2, and in the TAL
where it was co-localized with COX-2.20 This finding suggests
that AVP regulates nNOS and COX-2 through V1aR at
coexpressed cells and that the blockade of V1aR leads to the
suppression of nNOS and COX-2, resulting in reduced renin
activity.
Decreased plasma aldosterone level due to impaired AVP-
stimulated aldosterone release from adrenal glands in V1aR/
mice. Aldosterone secretion is known to be regulated by
factors such as AVP, angiotensin II, and adrenocorticotropic
hormone.25 As aldosterone levels were decreased in V1aR/
mice, aldosterone release from adrenal gland cells in response
to AVP stimulation was examined. As in previous reports on
human adrenal gland,26 AVP stimulated aldosterone release
from the dispersed adrenal gland cells of WT mice, and
this response was inhibited by the V1aR antagonist, implying
that AVP mediates aldosterone release from the adrenal
glands in mice.27 Supporting this finding, AVP-induced
aldosterone release from the adrenal gland cells of V1aR/
mice was impaired, whereas there was no difference in
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adrenocorticotropic hormone-induced aldosterone release
between V1aR/ and WT mice.27 This finding, observed
both in V1aR/ mice and in mice treated with the selective
antagonist, shows that blockade of the AVP/V1aR pathway
could lead to suppression of the signaling pathways of
aldosterone production and/or secretion in the adrenal
cortex, resulting in a decrease in the plasma aldosterone
level. Thus, the decreased plasma aldosterone levels observed
in V1aR/ mice could be caused by the suppression of RAS
activity and the impairment of AVP-stimulated aldosterone
secretion, although, in vivo, the RAS has a more major role
in regulating plasma aldosterone in the adrenal gland than
AVP-stimulated aldosterone secretion does.
Lower plasma volume due to the increased urine volume
caused by altered V2R–AQP2 function in V1aR/ mice. As the
RAS and tubuloglomerular feedback were altered due to the
lack of V1aR expression in V1aR/mice, we further assessed
their renal function. Urine volume was greater and urine
osmolarity was lower in V1aR/ mice than in WT mice,
particularly when water was loaded. The GFR, urinary NaCl
excretion, AVP-dependent cAMP generation, and V2R and
AQP2 expression in the kidney were lower in the mutant
mice, indicating that the diminished GFR and V2R–AQP2
system led to impaired urinary concentration in V1aR/
mice.20 In addition, increased renal vascular resistance and
decreased NO production in V1aR/ mouse kidneys under
the basal condition could indicate impairment of tubuloglo-
merular feedback in mutant mice.20 Angiotensin II facilitates
the AVP-stimulated V2R–AQP2 system.28 This observation,
taken together with the data from this study, indicates that
AVP can regulate body fluid homeostasis through V1aR in
macula densa cells by activating the RAS and subsequently
the V2R–AQP2 system, and that AVP/V1aR signaling may
have a part in tubuloglomerular feedback (Aoyagi T et al.,20
Figure 1). In general, a decrease in RAS activity could be
expected to lead to higher levels of Na excretion and polyuria,
but the disruption of V1aR resulted in decreased urinary Na
excretion and polyuria. To understand this discrepancy, we
will have to measure the fractional excretion of Na in future
studies. These data may explain whether alterations in
sodium excretion have their basis in tubular re-absorption
or in filtered load.
Comparison between V1aR/ mice and Brattleboro rats
AVP-deficient Brattleboro rats are well known as a model of
central diabetes insipidus; they exhibit normal blood pressure
despite impaired baroreflex and polyuria, whereas V1aR/
mice exhibit hypotension.29 Hypersecretion of renin due to
hyperactivity of the sympathetic nerve may help maintain
normotensive status in Brattleboro rats.30 Conversely, our
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Figure 1 | Schematic representation of the regulation of body
fluid retention by vasopressin and vasopressin receptor type
V1a and V2. Hyperosmolarity and decreased plasma volume
under the water-deprived condition lead to secretion of
vasopressin (AVP) from the posterior pituitary, which can bind to
V1a receptor (V1aR) in macula densa cells and to V2 receptor
(V2R) in collecting duct cells. AVP/V1aR stimulates the expression
of neuronal nitric oxide synthase (nNOS) and cyclooxygenase
(COX)-2, leading to the production of NO and prostaglandin E2
(PGE2) by macula densa cells, respectively. Both NO and PGE2
stimulate renin production from granule cells, and subsequent
increases in angiotensin II and aldosterone levels promote water
reabsorption. AVP/V2R enhances translocation of aquaporin
(AQP)-2 to the apical membrane from the cytoplasm. Water
reabsorption is further accelerated by the AVP/V1aR-stimulated
renin–angiotensin system (RAS). The AVP/V2R system and the RAS
enhanced by AVP/V1a critically regulate body fluid retention.
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Figure 2 |Contribution of vasopressin and vasopressin
receptor type V1a and V2 in the regulation of blood pressure
homeostasis. Blood pressure could be controlled by changes in
body fluid, cardiac output, and vascular contraction. Activation of
the AVP/V2R system induces the translocation of AQP2 and water
reabsorption in the kidney. The AVP/V1aR system, on the other
hand, stimulates RAS activity and aldosterone release. AVP also
directly stimulates aldosterone secretion from the adrenal grand.
In addition, AVP stimulates vascular contraction through V1aR.
V1aR also enhances baroreflex sensitivity, which controls the heart
rate. Central AVP/V1aR activates sympathetic nerve outflow
and regulates vascular as well as cardiac functions. These
V1aR-mediated cardiovascular and body-fluid-homeostasis effects
could have crucial roles in blood pressure regulation in health and
disease. Broad arrows indicate a physiological pathway directly
regulated by V1aR. ACE, angiotensin-converting enzyme; AQP2,
aquaporin-2; AVP, vasopressin; COX2, cyclooxygenase-2; nNOS,
neuronal nitric oxide synthase; RAS, renin–angiotensin system;
V1aR, V1a receptor; V2R, V2 receptor.
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observations of V1aR/ mice indicated that their decreased
sympathetic nerve activity may reduce the secretion of renin
in addition to impairing the tubuloglomerular feedback
system. Hence, dysfunction of RAS due to blockade of V1aR
led to hypotension in V1aR/ mice.
CONCLUSION
In summary, AVP has a crucial role in regulating blood
pressure through V1aR by stimulating vascular contractions,
arterial baroreceptor reflex, sympathetic nerve activity, and
water re-absorption, and blockade of the AVP/V1aR signal
results in decreased blood pressure (Figure 2). Studies using
the knockout model have several limitations, including the
difficulty of determining cause and effect, the difficulty of
determining direct versus indirect effects, and the possibility
of problems occurring due to the lifetime deletion of the
receptor causing functional compensations. In addition, the
importance of the observed knockout phenotype needs to be
further verified through studies involving other pharmaco-
logical or genetic interventions. Nevertheless, knockout
studies such as ours will provide valuable information and
clues contributing to the investigation of the mechanisms of
AVP/V1aR signaling in humans.
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